Synthetic high-density lipoprotein-like nanoparticles as cancer therapy

Cancer Treatment and Research

Volumn 166, Issue , 2015, Pages 129-150

  McMahon, Kaylin M ^a,b   Foit, Linda ^a,b   Angeloni, Nicholas L ^a,b   Giles, Francis J ^c   Gordon, Leo I ^a   Thaxton, C Shad ^a,b,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Simpson Querrey Institute for BioNanotechnology   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer therapy; Cholesterol; Delivery; High density lipoprotein; Nanotechnology; siRNA

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; COMPLEMENTARY DNA; DOXORUBICIN; FENRETINIDE; FOLATE RECEPTOR 1; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN LIKE NANOPARTICLE; MICRORNA; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; SCAVENGER RECEPTOR BI; SINGLE STRANDED DNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALRUBICIN; ANTINEOPLASTIC AGENT; NANOCONJUGATE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTITHROMBOTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER THERAPY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COLORECTAL CANCER; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; ISCHEMIC HEART DISEASE; LIVER CELL CARCINOMA; NANOENCAPSULATION; NEOPLASM; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVERSE CHOLESTEROL TRANSPORT; TUMOR GROWTH; ANIMAL; CHEMISTRY; NANOMEDICINE; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; NANOCONJUGATES; NANOMEDICINE; NEOPLASMS;

EID: 84928544649     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-16555-4_6     Document Type: Article

References (104)

1. Camont L, Chapman MJ, Kontush A (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17(10):594-603. doi:10.1016/J. Molmed.05.013
2. Xu S, Laccotripe M, Huang X et al (1997) Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 38(7):1289-1298
3. Warnick GR, McNamara JR, Boggess CN et al (2006) Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 26(4):803-846. doi:Doi 10.1016/J. Cll.2006.07.005
4. Tabet F, Rye KA (2009) High-density lipoproteins, inflammation and oxidative stress. Clin Sci 116(1-2):87-98. doi:10.1042/Cs20080106
5. Damiano MG, Mutharasan RK, Tripathy S et al (2013) Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 65 (5):649-662. doi:10.1016/j.addr.2012.07.013
6. Rosenson RS, Brewer HB, Chapman MJ et al (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57 (3):392-410. doi:10.1373/Clinchem.2010.155333
7. Asztalos BF, Tani M, Schaefer EJ (2011) Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 22(3):176-185. doi:10.1097/MOL.0b013e3283468061
8. Robert O, Bonow EA (eds) (2012) Braunwald's heart disease-a textbook of cardiovascular medicine, 9th edn. Elsevier Saunders, Philadelphia, PA
9. Ikonen E (2008) Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9(2):125-138. doi:10.1038/nrm2336
10. Calabresi L, Gomaraschi M, Rossoni G et al (2006) Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. Pharmacol Therapeut 111(3):836-854. doi:10.1016/J.Pharmthera.01.003
11. Silva RAGD, Huang R, Morris J et al (2008) Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Nat Acad Sci USA 105(34):12176-12181. doi:10.1073/Pnas.0803626105
12. Segrest JP, Li L, Anantharamaiah GM et al (2000) Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 11(2):105-115. doi:10.1097/00041433- 200004000-00002
13. Cheung MC, Albers JJ (1982) Distribution of high-density lipoprotein particles with different apoprotein composition-Particles with a-I and a-Ii and Particles with a-I but No a-Ii. J Lipid Res 23(5):747-753
14. Vickers KC, Palmisano BT, Shoucri BM et al (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13(4):423-U182. doi:10.1038/Ncb2210
15. Liu X, Suo R, Xiong SL et al (2013) HDL drug carriers for targeted therapy. Clin Chim Acta; Int J Cin Chem 415:94-100. doi:10.1016/j.cca.2012.10.008
16. Vickers KC, Remaley AT (2013) Functional diversity of HDL cargo. J Lipid Res doi:10. 1194/jlr.R035964
17. Pirillo A, Norata GD, Catapano AL (2013) High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 124(2):116-125. doi:10.1159/000346463
18. Feig JE, Hewing B, Smith JD et al (2014) High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 114(1):205-213. doi:10. 1161/CIRCRESAHA.114.300760
19. Rader DJ, Alexander ET, Weibel GL et al (2009) The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50(Suppl):S189-S194. doi:10.1194/jlr.R800088-JLR200
20. Gomaraschi M, Ossoli A, Vitali C et al (2013) HDL and endothelial protection: examining evidence from HDL inherited disorders. Clin Lipidol 8(3):361-370. doi:10.2217/Clp.13.30
21. Nicholls SJ, Dusting GJ, Cutri B et al (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111(12):1543-1550. doi:10.1161/01.Cir. 0000159351.95399.50
22. Cockerill GW, Rye KA, Gamble JR et al (1995) High-density-lipoproteins inhibit cytokineinduced expression of endothelial-cell adhesion molecules. Arterioscler Thromb Vasc 15 (11):1987-1994
23. Navab M, Imes SS, Hama SY et al (1991) Monocyte transmigration induced by modification of low-density-lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic Protein-1 synthesis and is abolished by high-density-lipoprotein. J Clin Invest 88(6):2039-2046. doi:10.1172/Jci115532
24. Gordon LI, Bass J, Yachnin S (1980) Inhibition of human polymorphonuclear leukocyte chemotaxis by oxygenated sterol compounds. Proc Nat Acad Sci USA 77(7):4313-4316
25. Yachnin S, Streuli RA, Gordon LI et al (1979) Alteration of peripheral blood cell membrane function and morphology by oxygenated sterols; a membrane insertion hypothesis. Curr Top Hematol 2:245-271
26. Kontush A, Chapman MJ (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 21(4):312-318. doi:10.1097/Mol. 0b013e32833bcdc1
27. Davidson WS, Silva RAGD, Chantepie S et al (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters relevance to antioxidative function. Arterioscler Thromb Vasc 29(6):870-U234. doi:10.1161/Atvbaha.109.186031
28. Subramanian VS, Goyal J, Miwa M et al (1999) Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochim Biophys Acta 1439(1):95-109
29. Mineo C, Deguchi H, Griffin JH et al (2006) Endothelial and antithrombotic actions of HDL. Circ Res 98(11):1352-1364. doi:10.1161/01.RES.0000225982.01988.93
30. Yuhanna IS, Zhu Y, Cox BE et al (2001) High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7(7):853-857. doi:10.1038/ 89986
31. Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10(4):171-178. doi:10.1016/j.molmed.2004.02.008
32. Farmer JA, Liao J (2011) Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr atherosclerosis rep 13(2):107-114. doi:10.1007/ s11883-011-0166-3
33. Naqvi TZ, Shah PK, Ivey PA et al (1999) Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 84 (9):1011-1017
34. Calkin AC, Drew BG, Ono A et al (2009) Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120(21):2095-2104. doi:10.1161/CIRCULATIONAHA.109.870709
35. Simons K, Ikonen E (2000) How cells handle cholesterol. Science 290(5497):1721-1726. doi:10.1126/science.290.5497.1721
36. Clendening JW, Pandyra A, Boutros PC et al (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Nat Acad Sci USA 107(34):15051-15056. doi:10. 1073/pnas.0910258107
37. Ginestier C, Monville F, Wicinski J et al (2012) Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 30(7):1327-1337. doi:10.1002/stem.1122
38. Cruz PM, Mo H, McConathy WJ et al (2013) The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front pharmacol 4:119. doi:10.3389/fphar.2013.00119
39. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746):34-47. doi:10.1126/science.3513311
40. Olson RE (1998) Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr 128(2):439s-443s
41. Chapman MJ (1980) Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21(7):789-853
42. Gorin A, Gabitova L, Astsaturov I (2012) Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol 12(6):710-716. doi:10.1016/j.coph.2012.06.011
43. Brown AJ (2007) Cholesterol, statins and cancer. Clin Exp Pharmacol Physiol 34(3):135-141. doi:10.1111/j.1440-1681.2007.04565.x
44. Simons K, Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 11(10):688-699. doi:10.1038/nrm2977
45. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387(6633):569-572. doi:10.1038/42408
46. Niendorf A, Nagele H, Gerding D et al (1995) Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer J Int Du Cancer 61(4):461-464
47. Solomon KR, Freeman MR (2011) The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am 38(3):243-259. doi:10.1016/j.ucl.2011.04.001
48. Rotheneder M, Kostner GM (1989) Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer J Int Du Cancer 43(5):875-879
49. Uda S, Accossu S, Spolitu S et al (2012) A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line. Tumour Biol: J Int Soc Oncodevelopmental Biol Med 33(2):443-453. doi:10.1007/s13277-011-0270-6
50. Danilo C, Frank PG (2012) Cholesterol and breast cancer development. Curr Opin Pharmacol 12(6):677-682. doi:10.1016/j.coph.2012.07.009
51. Navab M, Reddy ST, Van Lenten BJ et al (2009) The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50(Suppl):S145-S149. doi:10.1194/jlr.R800036-JLR200
52. Eren E, Yilmaz N, Aydin O (2012) High density lipoprotein and it's dysfunction. Open Biochem J 6:78-93. doi:10.2174/1874091X01206010078
53. Leon CG, Locke JA, Adomat HH et al (2010) Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70(4):390-400. doi:10.1002/pros.21072
54. Shahzad MMK, Mangala LS, Han HD et al (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309-U142. doi:10.1593/Neo.101372
55. Llaverias G, Danilo C, Mercier I et al (2011) Role of cholesterol in the development and progression of breast cancer. Am J Pathol 178(1):402-412. doi:10.1016/j.ajpath.2010.11.005
56. Muntoni S, Atzori L, Mereu R et al (2009) Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis: NMCD 19(3):218-225. doi:10.1016/j.numecd.2008.06.002
57. Danilo C, Gutierrez-Pajares JL, Mainieri MA et al (2013) Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res: BCR 15(5):R87. doi:10.1186/bcr3483
58. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3 (1):16-20. doi:10.1021/Nn900002m
59. Sabnis N, Lacko AG (2012) Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv 3(5):599-608
60. Huynh E, Zheng G (2013) Engineering multifunctional nanoparticles: all-in-one versus onefor- all. Wiley Interdisc Rev Nanomed Nanobiotechnol 5(3):250-265. doi:10.1002/wnan. 1217
61. Ng KK, Lovell JF, Zheng G (2011) Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 44(10):1105-1113. doi:10.1021/Ar200017e
62. Sabnis N, Nair M, Israel M et al (2012) Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomed 7:975-983. doi:10.2147/Ijn.S28029
63. Lacko AG, Nair M, Paranjape S et al (2002) High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 22(4):2045-2049
64. Liadaki KN, Liu T, Xu S et al (2000) Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 275(28):21262-21271. doi:10.1074/jbc.M002310200
65. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116(12):3090-3100. doi:10.1172/Jci30163
66. Ghosh M, Singh AT, Xu W et al (2011) Curcumin nanodisks: formulation and characterization. Nanomedicine 7(2):162-167. doi:10.1016/j.nano.2010.08.002
67. Singh AT, Evens AM, Anderson RJ et al (2010) All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol 150(2):158-169. doi:10.1111/j.1365-2141.2010.08209.x
68. Singh AT, Ghosh M, Forte TM et al (2011) Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 52(8):1537-1543. doi:10.3109/10428194.2011.584253
69. Jia JT, Xiao Y, Liu JP et al (2012) Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci- US 101(8):2900-2908. doi:10.1002/Jps.23210
70. Wang J, Jia JT, Liu JP et al (2013) Tumor targeting effects of a novel modified paclitaxelloaded discoidal mimic high density lipoproteins. Drug Deliv 20(8):356-363. doi:10.3109/ 10717544.2013.834418
71. Zhang M, Jia J, Liu J et al (2013) A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J Pharm Sci 8 (1):11-18. doi:http://dx.doi.org/10.1016/j.ajps.2013.07.002
72. Sabnis N, Pratap S, Akopova I et al (2013) Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front Pediatr 1:6. doi:10.3389/fped.2013.00006
73. Wang BL, Yuan Y, Han L et al (2014) Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J Drug Target 22(1):76-85. doi:10.3109/1061186x. 2013.839687
74. Yuan Y, Wang WN, Wang BL et al (2013) Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 21(4):367-374. doi:10. 3109/1061186x.2012.757769
75. Lin Q, Chen J, Ng KK et al (2013) Imaging the cytosolic drug delivery mechanism of HDLlike nanoparticles. Pharm Res. doi:10.1007/s11095-013-1046-z
76. Reddy ST, Navab M, Anantharamaiah GM et al (2014) Searching for a successful HDLbased treatment strategy. Biochim Biophys Acta 1841 1:162-167
77. Knecht TP, Pittman RC (1989) A plasma-membrane pool of cholesteryl esters that may mediate the selective uptake of cholesteryl esters from high-density lipoproteins. Biochim Biophys Acta 1002(3):365-375. doi:10.1016/0005-2760(89)90351-2
78. Pittman RC, Knecht TP, Rosenbaum MS et al (1987) A nonendocytotic mechanism for the selective uptake of high-density lipoprotein-associated cholesterol esters. J Biol Chem 262 (6):2443-2450
79. Mathew S, Murakami T, Nakatsuji H et al (2013) Exclusive photothermal heat generation by a gadolinium bis(naphthalocyanine) complex and inclusion into modified high-density lipoprotein nanocarriers for therapeutic applications. ACS Nano 7(10):8908-8916. doi:10. 1021/Nn403384k
80. Ng KK, Lovell JF, Vedadi A et al (2013) Self-assembled porphyrin nanodiscs with structuredependent activation for phototherapy and photodiagnostic applications. ACS Nano 7 (4):3484-3490. doi:10.1021/Nn400418y
81. Corbin IR (2013) Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol Biol 1049:467-480. doi:10.1007/978-1-62703-547-7_35
82. Kalli KR, Oberg AL, Keeney GL et al (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108(3):619-626. doi:10.1016/j.ygyno.2007.11.020
83. Corbin IR, Ng KK, Ding L et al (2013) Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine 8(6):875-890. doi:10.2217/nnm.12.137
84. Bijsterbosch MK, Rump ET, De Vrueh RLA et al (2000) Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res 28(14):2717-2725. doi:10.1093/Nar/28.14.2717
85. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014):173-178. doi:10.1038/ Nature03121
86. Lorenz C, Hadwiger P, John M et al (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14 (19):4975-4977. doi:10.1016/J.Bmcl.07.018
87. Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25(10):1149-1157. doi:10.1038/nbt1339
88. Thaxton CS, Daniel WL, Giljohann DA et al (2009) Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 131(4):1384-1385. doi:10.1021/ja808856z
89. Luthi AJ, Zhang H, Kim D et al (2012) Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 6(1):276-285. doi:10. 1021/nn2035457
90. Yang S, Damiano MG, Zhang H et al (2013) Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Nat Acad Sci USA 110(7):2511-2516. doi:10.1073/pnas.1213657110
91. McMahon KM, Mutharasan RK, Tripathy S et al (2011) Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 11(3):1208-1214. doi:10.1021/nl1041947
92. Tripathy S, Vinokour E, McMahon KM et al (2014) High-density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part Part Syst Charact. doi:10.1002/ ppsc.201400036
93. Yang M, Jin HL, Chen JA et al (2011) Efficient cytosolic delivery of siRNA using HDLmimicking nanoparticles. Small 7(5):568-573. doi:10.1002/Smll.201001589
94. Shahzad MM, Mangala LS, Han HD et al (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309-319
95. Ding Y, Wang W, Feng MQ et al (2012) A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33(34):8893-8905. doi:10.1016/J.Biomaterials.08.057
96. Dong Y, Love KT, Dorkin JR et al (2014) Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Nat Acad Sci USA 111(11):3955-3960. doi:10.1073/pnas.1322937111
97. Nakayama T, Butler JS, Sehgal A et al (2012) Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mole Ther: J Am Soc Gene Ther 20 (8):1582-1589. doi:10.1038/mt.2012.33
98. Fischer NO, Weilhammer DR, Dunkle A et al (2014) Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. Plos ONE 9(3). doi:ARTN e93342 DOI 10.1371/ journal.pone.0093342
99. Zheng Y, Liu YY, Jin HL et al (2013) Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 3(7):477-486. doi:10.7150/Thno.6617
100. Zhang ZH, Chen J, Ding LL et al (2010) HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3):430-437. doi:10.1002/Smll.200901515
101. Su F, Grijalva V, Navab K et al (2012) HDL Mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 11(6):1311-1319. doi:10.1158/1535-7163.Mct-11-0905
102. Rui MJ, Tang HL, Li Y et al (2013) Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharm Res-Dordr 30(5):1203-1214. doi:10.1007/s11095- 012-0957-4
103. Kim Y, Fay F, Cormode DP et al (2013) Single step reconstitution of multifunctional highdensity lipoprotein-derived nanomaterials using microfluidics. ACS Nano 7(11):9975-9983. doi:10.1021/nn4039063
104. Lin QY, Chen J, Jin HL et al (2012) Efficient systemic delivery of siRNA by using highdensity lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 7(12):1813-1825. doi:10.2217/Nnm.12.73